About Us
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers.
-
Regulatory August 24, 2023Interim report for the period January 1, 2023 – June 30, 2023
-
Non Regulatory August 4, 2023Vivesto announces early termination of patient enrollment in the investigator-initiated Phase 1b Docetaxel micellar study
-
Non Regulatory June 16, 2023Vivesto announces positive Paccal Vet FDA pre-submission meeting
Vivesto published its Q2 report for 2023 on August 24, 2023, at 08.00 am CEST.